Pyramax Granules

Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium for delayed-release oral suspension is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing a …

• Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD
• Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 40 kg 40 mg Once Daily for up to 8 wks Maintenance of Healing of Erosive Esophagitis
• Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
• Adults 40 mg Twice Daily * Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions Recommended Dosing Schedule Pantoprazole sodium is supplied as delayed-release granules in packets for preparation of oral suspensions
• The recommended dosages are outlined in Table 1
• Table 1: Recommended Dosing Schedule for Pantoprazole Sodium for Delayed-Release Oral Suspension Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD
• Adults 40 mg Once daily for up to 8 weeks* Children (5 years and older) ≥ 40 kg 40 mg Once daily for up to 8 weeks Maintenance of Healing of Erosive Esophagitis
• Adults 40 mg Once Daily*** Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
• Adults 40 mg Twice Daily** * For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium for delayed-release oral suspension may be considered. ** Dosage regimens should be adjusted to individual patient needs and should continue for as long as clinically indicated
• Doses up to 240 mg daily have been administered. …

For Delayed-Release Oral Suspension: 40 mg pantoprazole USP, off-white to pale yellowish to greyish brown, enteric-coated granules in a unit dose packets For Delayed-Release Oral Suspension: 40 mg pantoprazole ( 3 )

• The safety and effectiveness of pantoprazole for short-term treatment (up to eight weeks) of EE associated with GERD have been established
• In pediatric patients 1 year through 16 years of age
• Effectiveness for EE has not been demonstrated in patients less than 1 year of age
• In addition, for patients less than 5 years of age, there is no appropriate dosage strength in an age-appropriate formulation available
• Therefore, pantoprazole is indicated for the short-term treatment of EE associated with GERD for patients 5 years and older. …

In short-term US clinical trials, EE healing rates in the 107 elderly patients (≥65 years old) treated with pantoprazole were similar to those found in patients under the age of 65. The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age.

• Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use)
• Gastric Malignancy Advise patients to return to their healthcare provider if they have a suboptimal response or an early symptomatic relapse [see Warnings and Precautions ]
• Acute Tubulointerstitial Nephritis Advise patients to call their healthcare provider immediately if they experience signs and/or symptoms associated with acute tubulointerstitial nephritis [see Contraindications , Warnings and Precautions ] . …

• Pantoprazole sodium for delayed-release oral suspension is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole
• Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions , Adverse Reactions ] . …

Table 4 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with pantoprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 4: Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. …

Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing. ( 5.1 ) Acute Tubulointerstitial Nephritis : Discontinue treatment and evaluate patients. ( 5.2 ) Clostridium difficile- Associated Diarrhea : PPI therapy may be associated with increased risk of Clostridium difficile- associated diarrhea. ( 5.3 ) Bone Fracture : Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. …

The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions ( 5.2 )] Clostridium difficile- Associated Diarrhea [see Warnings and Precautions ( 5.3 )] Bone Fracture [see Warnings and Precautions ( 5.4 )] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.5 )] Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions ( 5.6 )] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions ( 5.7 )] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions ( 5.8 )] Fundic Gland Polyps [see Warnings and Precautions ( 5.10 )] Most common adverse reactions a …

8.1 Pregnancy Risk Summary Available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pantoprazole. In animal reproduction studies, no evidence of adverse development outcomes was observed with pantoprazole. …

Experience in patients taking very high doses of pantoprazole (greater than 240 mg) is limited. Spontaneous post-marketing reports of overdose are generally within the known safety profile of pantoprazole. Pantoprazole is not removed by hemodialysis. In case of overdosage, treatment should be symptomatic and supportive. Single oral doses of pantoprazole at 709 mg/kg, 798 mg/kg, and 887 mg/kg were lethal to mice, rats, and dogs, respectively. The symptoms of acute toxicity were hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. …

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.